TPC-1 Cells
€750.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The TPC-1 cell line originates from a papillary thyroid carcinoma (PTC) and is widely utilized as a model for studying the molecular mechanisms of thyroid cancer. This cell line is notable for harboring the RET/PTC1 rearrangement, a hallmark genetic alteration in PTC. The RET/PTC1 fusion results in constitutive activation of RET tyrosine kinase signaling, driving oncogenic processes such as increased cellular proliferation, survival, and differentiation. This genetic feature has made TPC-1 a valuable tool in understanding thyroid oncogenesis and in evaluating targeted therapies. Derived from a well-differentiated thyroid tumor, TPC-1 retains epithelial characteristics and exhibits features associated with thyroid differentiation, including thyroglobulin production. TPC-1 has been extensively studied for its signaling pathways, particularly the MAPK and PI3K/AKT pathways, which are activated downstream of RET/PTC1. These pathways are critical to thyroid tumor progression and represent targets for therapeutic intervention. In addition to its genetic and cellular characteristics, TPC-1 has been employed in in vitro and in vivo models to investigate the effectiveness of RET inhibitors and other targeted therapies. Its well-characterized genetic background and responsiveness to pharmacological agents make it a crucial model for translational research in thyroid cancer. Studies comparing TPC-1 with other thyroid cancer cell lines have also highlighted its role in identifying common and distinct molecular features of thyroid cancer subtypes, aiding in the development of personalized treatment strategies. |
|---|---|
| Organism | Human |
| Tissue | Thyroid |
| Disease | Thyroid gland papillary carcinoma |
| Synonyms | TPC1 |
Characteristics
| Age | Adult |
|---|---|
| Gender | Female |
| Morphology | Epithelial |
| Growth properties | Adherent |
Regulatory Data
| Citation | TPC-1 (Cytion catalog number 305054) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_6298 |
Biomolecular Data
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS, 4.5 g/L Glucose |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305054-181124 | Certificate of Analysis | 23. May. 2025 | 305054 |
Material Transfer Agreement
If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.
For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.
Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement.